Chinese government okays Sumitomo investment

After 16 months of wrangling, Japanese investor secures 20% in Henan Topfond Pharmaceutical.
Sumitomo, one of JapanÆs largest trading corporations, announced yesterday March 13 that it has completed the acquisition of a strategic interest in a profitable Chinese drug-maker. The deal will enable Sumitomo, which also recently acquired a Japanese drug maker, to expand its presence in China, and to source Henan TopfondÆs range of generic drugs for sales abroad.

The deal represents the first such strategic stake in a Chinese company by Sumitomo, which has previously been restricted to joint ventures. Although the consideration was reportedly less than $25 million no sales price has been announced, the deal has been dogged by lengthy delays. These were due to a mixture of nationalistic and technical reasons, say...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222